Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20502482 | 0.98 | LMNA (0.59) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL10416921 | 0.89 | PGR (0.61) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL4204011 | 0.87 | PGR (0.62) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL27363449 | 0.84 | POLB (0.53) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL21033859 | 0.84 | LMNA (0.59) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL11785316 | 0.84 | LMNA (0.59) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL5763668 | 0.84 | LMNA (0.59) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL1645211 | 0.84 | CA1 (0.62) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL28082173 | 0.83 | TSHR (0.74) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL17227610 | 0.82 | LMNA (0.61) | LMNASMN1; SMN2MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4258191-A | STARTING WITH 4-BUTYRYLAMINO-3-METHOXY-NITROBENZENE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH, EDUCATION AND WELFARE (US) | 1981-03-24 | — | — | US | claimed |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| EP-3328843-B1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2022-10-26 | — | — | EP | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
| CN-107922362-B | 1,3, 4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | 株式会社钟根堂 | 2021-06-15 | — | — | CN | disclosed |
| WO-2021047674-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | 南京明德新药研发有限公司 | 2021-03-18 | — | — | WO | disclosed |
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2020-10-29 | — | — | US | disclosed |
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-09-06 | — | — | US | disclosed |
| WO-2001064634-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
| EP-0142085-B1 | METHOD OF PREPARING MICROSPHERES FOR INTRAVASCULAR DELIVERY | Mosier, Benjamin (US) | 1988-08-24 | — | — | EP | disclosed |
| US-4704397-A | ANTITUMOR AGENTS | WARNER-LAMBERT COMPANY (US) | 1987-11-03 | — | — | US | disclosed |
| EP-0142085-A2 | Method of preparing microspheres for intravascular delivery | Mosier, Benjamin (US) | 1985-05-22 | — | — | EP | disclosed |
| US-4492720-A | DISSOLVING, DISPERSION IN MATRIX, EVAPORATION OF SOLVENT | MOSIER BENJAMIN | 1985-01-08 | — | — | US | disclosed |
| EP-0035862-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 4'-(9-ACRIDINYLAMINO) METHANESULFON-M-ANISIDIDE, THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH SALTS | WARNER-LAMBERT COMPANY (US) | 1984-06-13 | — | — | EP | disclosed |
| US-4399283-A | ANTITIMOR AGENTS | WARNER LAMBERT COMPANY (US) | 1983-08-16 | — | — | US | disclosed |
| US-4258191-A | STARTING WITH 4-BUTYRYLAMINO-3-METHOXY-NITROBENZENE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH, EDUCATION AND WELFARE (US) | 1981-03-24 | — | — | US | disclosed |
| US-4258191-A | STARTING WITH 4-BUTYRYLAMINO-3-METHOXY-NITROBENZENE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH, EDUCATION AND WELFARE (US) | 1981-03-24 | — | — | US | disclosed |
| US-4258191-A | STARTING WITH 4-BUTYRYLAMINO-3-METHOXY-NITROBENZENE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH, EDUCATION AND WELFARE (US) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | LMNA 4785/4885SMN1; SMN2 3741/4885MEN1 3406/4885 |
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC6, HDAC2 | LMNA 3360/4885SMN1; SMN2 1602/4885MEN1 4654/4885 |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | CRBN, CRKL, NCOR1 | LMNA 3513/4885SMN1; SMN2 2827/4885MEN1 3717/4885 |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | LMNA 4785/4885SMN1; SMN2 3741/4885MEN1 3406/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | LMNA 4785/4885SMN1; SMN2 3741/4885MEN1 3406/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | LMNA 4785/4885SMN1; SMN2 3741/4885MEN1 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.